NASDAQ:VYNE
Vyne Therapeutics Inc Stock News
$2.77
+0.0700 (+2.59%)
At Close: May 17, 2024
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Lags Revenue Estimates
09:57am, Wednesday, 10'th Nov 2021
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of -5.88% and -12.51%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
04:50pm, Thursday, 28'th Oct 2021
VYNE Therapeutics Inc. (VYNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
08:00am, Thursday, 28'th Oct 2021
BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third qua
VYNE Therapeutics' BET Inhibitor Shows Encouraging Preclinical Action
01:45pm, Tuesday, 26'th Oct 2021
VYNE Therapeutics Inc (NASDAQ: VYNE) announced preclinical data for VYN201, its pan-bromodomain and extra-terminal (BET) inhibitor. The data showed that VYN201 significantly reduced the expression
VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference
08:00am, Monday, 20'th Sep 2021
BRIDGEWATER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will presen
VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference
08:00am, Wednesday, 08'th Sep 2021
BRIDGEWATER, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will presen
VYNE Therapeutics Inc. (VYNE) CEO Dave Domzalski on Q2 2021 Results - Earnings Call Transcript
02:49pm, Thursday, 12'th Aug 2021
VYNE Therapeutics Inc. (VYNE) CEO Dave Domzalski on Q2 2021 Results - Earnings Call Transcript
Recap: VYNE Therapeutics Q2 Earnings
08:12am, Thursday, 12'th Aug 2021
Shares of VYNE Therapeutics (NASDAQ:VYNE) fell 15.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 57.32% year over year to ($0.35), which were
Company announced license agreement with In4Derm Limited for BETi platform earlier this morning
VYNE Therapeutics' (VYNE) CEO Dave Domzalski on Q1 2021 Results - Earnings Call Transcript
01:07pm, Thursday, 06'th May 2021
VYNE Therapeutics' (VYNE) CEO Dave Domzalski on Q1 2021 Results - Earnings Call Transcript
VYNE Therapeutics: Rapidly Progressing In The Dermatology Market
02:28pm, Wednesday, 07'th Apr 2021
VYNE has two approved products and a late-stage asset.
VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences
04:01pm, Thursday, 04'th Mar 2021
BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will presen
VYNE Therapeutics Inc. (VYNE) Reports Q4 Loss, Misses Revenue Estimates
09:08am, Thursday, 04'th Mar 2021
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 14.00% and -12.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st
VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update
07:00am, Thursday, 04'th Mar 2021
Conference call and live webcast to discuss financial results and new FMX114 program in atopic dermatitis today, Thursday, March 4, 2021, at 8:30 am Eastern Time Conference call and live webcast to di
VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis
08:00am, Monday, 01'st Mar 2021
Announces promising preclinical data on FMX114
